Request Demo
Last update 05 Jun 2025
CTS-2190
Last update 05 Jun 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms CTS 2190, CTS2190 |
Target |
Action inhibitors |
Mechanism PRMT1 inhibitors(Protein arginine N-methyltransferase 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with CTS-2190NCT06224387
A Multi-center, Open-label, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS2190 in Patients With Solid Tumors
100 Clinical Results associated with CTS-2190
Login to view more data
100 Translational Medicine associated with CTS-2190
Login to view more data
100 Patents (Medical) associated with CTS-2190
Login to view more data
100 Deals associated with CTS-2190
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | Phase 2 | China | 26 Jun 2023 | |
| Pancreatic Cancer | Phase 2 | China | 26 Jun 2023 | |
| Triple Negative Breast Cancer | Phase 2 | China | 26 Jun 2023 | |
| Solid tumor | Phase 1 | United States | 17 Feb 2023 | |
| Metastatic castration-resistant prostate cancer | Preclinical | China | 29 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | Solid tumor arginine methyltransferase 1 (PRMT1) | asymmetric dimethylarginine (ADMA) | DNA damage response (DDR) ... View more | 38 | CTS2190 60-300 mg | jcywtidyqy(bhgmrsjcro) = 31.6% ddgypgpuof (oghyupkcpx ) View more | Positive | 30 May 2025 | |
NCT06224387 (ESMO2024) Manual  | Phase 1/2 | 15 | CTS2190 60 mg | cejukepzid(lteywmsrbk) = ruvjdvoufo zjujevzxov (fronorsqdr ) View more | Positive | 14 Sep 2024 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free